{"id":62469,"date":"2026-01-09T19:06:58","date_gmt":"2026-01-09T18:06:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/"},"modified":"2026-01-09T19:06:58","modified_gmt":"2026-01-09T18:06:58","slug":"vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/","title":{"rendered":"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis\u2019 largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021<\/i><\/li>\n<li>\n<i>Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief Operating Officer, helping to establish the company\u2019s early operational, scientific, and strategic foundation<\/i><\/li>\n<\/ul>\n<p>LOS ANGELES &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211;Vida Ventures (\u201cVida\u201d), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the company enters the public markets.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/5\/VV_Logo_Gradient_2025.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/22\/VV_Logo_Gradient_2025.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/5\/VV_Logo_Gradient_2025.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/21\/VV_Logo_Gradient_2025.jpg\"><\/a><\/p>\n<p>\nVida has supported Aktis since co-leading its Series A, beginning with early platform diligence and company building efforts and continuing through multiple private financings and strategic inflection points leading up to the IPO, with Vida\u2019s Helen Kim serving on the Aktis Board of Directors throughout this period. Vida is the second largest shareholder in the company leading up to the IPO.<\/p>\n<p>\n\u201cAktis represents the type of company Vida was envisioned to build and support, grounded in differentiated science, built with operational rigor, and developed through hands-on partnership,\u201d said Helen S. Kim, Senior Managing Director at Vida Ventures and Board Member at Aktis. \u201cAs Aktis prepares to enter the public markets, we are proud of the role we\u2019ve played in building the company and its potential to deliver transformative therapies for patients with cancer.\u201d<\/p>\n<p>\nAktis Oncology was co-founded by Brian Goodman, Ph.D., Managing Director at Vida Ventures, who served as the company\u2019s founding Chief Operating Officer until August 2022 and later, its Chief Business Officer until May 2024. Dr. Goodman helped translate foundational science into a scalable operating company working hand in hand with the management team led by Matthew Roden, Chief Executive Officer of Aktis, establishing critical capabilities and supporting Aktis\u2019 strategic collaboration with Eli Lilly, for a total deal valued at up to $1.2 billion.<\/p>\n<p>\n\u201cFrom the outset, our goal with Aktis was to build a company around a highly differentiated alpha-radiopharmaceutical platform based on miniproteins with the potential to meaningfully impact patients with solid tumors,\u201d said Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis. \u201cThat required not just strong science, but thoughtful company building by assembling the right capabilities, partnerships, and culture to support long-term execution. Seeing Aktis reach the public markets is a testament to the team and to the company\u2019s continued progress.\u201d<\/p>\n<p>\nFounded in 2020, Aktis Oncology is developing targeted alpha-particle therapies designed to selectively deliver potent radioactive payloads to tumor cells while minimizing damage to healthy tissue. The company had previously raised approximately $346 million in private capital and is advancing a pipeline led by AKY-1189, an actinium-225\u2013based radiopharmaceutical targeting Nectin-4\u2013expressing tumors, and AKY-2519, targeting B7-H3\u2013expressing tumors.<\/p>\n<p>\n<b>About Vida Ventures<\/b><\/p>\n<p>\nVida Ventures, LLC (\u201cVida\u201d), founded by Arie Belldegrun, MD, is a next-generation life sciences investment firm comprised of scientists, physicians, entrepreneurs and investors, who are passionate about building and funding breakthroughs in biomedicine. Vida\u2019s mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida currently has approximately $1.8 billion of capital commitment from blue-chip institutional investors, including top-tier endowments and foundations, sovereign wealth funds, pensions, financial institutions, family offices, fund-of-funds, and high net worth individuals. Vida has offices in Los Angeles, Boston, New York, and Fort Worth and is focused on identifying groundbreaking science and building innovative companies that lead to new areas of drug discovery and development. For more information on Vida Ventures, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vidaventures.com&amp;esheet=54392978&amp;newsitemid=20260109857776&amp;lan=en-US&amp;anchor=www.vidaventures.com&amp;index=1&amp;md5=d58677946c3341787a774544c3e9f287\" rel=\"nofollow\" shape=\"rect\">www.vidaventures.com<\/a>, on LinkedIn or follow on X @Vida_Ventures.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nJean- Philippe Kouakou-Zebouah<br \/>\n<br \/>Chief Financial Officer\/Chief Operating Officer<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;j&#112;&#x40;v&#105;&#x64;&#x61;v&#101;&#x6e;t&#117;&#x72;&#x65;s&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x6a;p&#x40;&#118;i&#x64;&#97;&#x76;&#101;n&#x74;&#117;&#x72;&#101;s&#x2e;&#99;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis\u2019 largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021 Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62469","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis\u2019 largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021 Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-09T18:06:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/22\/VV_Logo_Gradient_2025.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets\",\"datePublished\":\"2026-01-09T18:06:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/\"},\"wordCount\":670,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109857776\\\/en\\\/2687649\\\/22\\\/VV_Logo_Gradient_2025.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/\",\"name\":\"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109857776\\\/en\\\/2687649\\\/22\\\/VV_Logo_Gradient_2025.jpg\",\"datePublished\":\"2026-01-09T18:06:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109857776\\\/en\\\/2687649\\\/22\\\/VV_Logo_Gradient_2025.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260109857776\\\/en\\\/2687649\\\/22\\\/VV_Logo_Gradient_2025.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/","og_locale":"en_US","og_type":"article","og_title":"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Pharma Trend","og_description":"Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis\u2019 largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021 Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-09T18:06:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/22\/VV_Logo_Gradient_2025.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets","datePublished":"2026-01-09T18:06:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/"},"wordCount":670,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/22\/VV_Logo_Gradient_2025.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/","url":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/","name":"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/22\/VV_Logo_Gradient_2025.jpg","datePublished":"2026-01-09T18:06:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/22\/VV_Logo_Gradient_2025.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260109857776\/en\/2687649\/22\/VV_Logo_Gradient_2025.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vida-ventures-congratulates-aktis-oncology-on-its-entry-into-the-public-markets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62469"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62469\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}